SCHEMBL863449

SCHEMBL863449

[CH2]CCCCCc1ccc(F)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
RAB9A P51151 5/20 0.36
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
NPC1 O15118 3/20 0.36
STAT3 P40763 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.33
NFKB1 P19838 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15516735 0.84 CYP11B1 (0.43) CYP11B1CYP11B2RAB9ASMN1; SMN2NPC1
SCHEMBL10327386 0.81 RAB9A (0.54) RAB9AMAPTSMN1; SMN2NPC1STAT3
SCHEMBL19237057 0.81 RAB9A (0.54) RAB9AMAPTSMN1; SMN2NPC1STAT3
SCHEMBL10721748 0.79 RAB9A (0.51) RAB9AMAPTSMN1; SMN2NPC1STAT3
SCHEMBL9154233 0.79 MAPT (0.51) RAB9AMAPTSMN1; SMN2NPC1STAT3
SCHEMBL2095248 0.78 GAA (0.42) MAPTL3MBTL1KDM4EALDH1A1LMNA
SCHEMBL23124232 0.77 CYP2A6 (0.48) CYP11B1CYP11B2RAB9AMAPTSMN1; SMN2
SCHEMBL8662195 0.77 CYP11B1 (0.41) CYP11B1CYP11B2RAB9AMAPTSMN1; SMN2
SCHEMBL29745082 0.77 CYP2A6 (0.48) CYP11B1CYP11B2RAB9AMAPTSMN1; SMN2
SCHEMBL9154167 0.76 RAB9A (0.49) RAB9AMAPTSMN1; SMN2NPC1STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621278-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-08-07 EP claimed
US-8476302-B2 α-ketoamide derivatives useful endothelial lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-02 US claimed
WO-2012047580-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-04-12 WO claimed
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS LIPG, LIPA, LIPE CYP11B1 1515/4885CYP11B2 1768/4885RAB9A 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.